Table 5 Ongoing, active clinical trials in metastatic RCC involving small molecules in combination with other drugs
Target | NCT number | Drug | Combination drug/s or comparator drug* | Phase | Mechanism | Primary outcome | Status |
|---|---|---|---|---|---|---|---|
HDAC Inhibitor | NCT02619253 | Vorinostat | Pembrolizumab | I | Decreased proliferation, Apoptosis | MTD | Active not recruiting |
NCT03592472 | Abexinostat | Pazopanib | III | PFS | |||
NCT03024437 | Entinostat | Bevacizumab, Atezolizumab | I/II | Safety | Recruiting | ||
NCT03552380 | Entinostat | Nivolumab, Ipilimumab | II | Safety | Recruiting | ||
NCT03501381 | Entinostat | IL-2 high dose* | II | PFS | Recruiting | ||
NCT02718066 | HBI-8000 (Chidamide) | Nivolumab | I/II | Safety | Recruiting | ||
NCT01038778 | Entinostat | Aldeslukin | I/II | Safety, dose | Active not recruiting | ||
NCT02890069 | Panobinostat | PDR001,LCL16,everolimus | I/II | Safety | Recruiting | ||
Glutaminase Inhibitor | NCT03163667 | CB-839 (Telaglenastat) | Everolimus | II | Decreased cell proliferation and survival | PFS | Active not recruiting |
NCT03428217 | Cabozantinib | II | PFS | Active not recruiting | |||
NCT02771626 | Nivolumab | I/II | Safety, tolerability efficacy | Active not recruiting | |||
NCT03875313 | Talazoparib | I/II | Safety, dose | Recruiting | |||
HIF 2a Inhibitor | NCT03634540 | PT2977 | Cabozantinib | II | Impairs hypoxia, blocks transcription of several angiogenesis genes | ORR | Recruiting |
NCT03401788 | PT2977 | None | II | ORR | Active not recruiting | ||
NCT02974738 | PT2977 | None | I | Dose | Recruiting | ||
NCT02293980 | PT2385 | None | I | Dose | Active not recruiting | ||
CD73 Inhibitor | NCT03549000 | NZV930 | PDR001, NIR178 | I | Decreases tumour growth, promotes CTL-mediated immune response | Safety, dose | Recruiting |
NCT03454451 | CPI-006 | Pembrolizumab/CP-444 | I | Safety, dose | Recruiting | ||
Arginase Inhibitor | NCT02903914 | CB-1158 | None | I/II | Blocks Arg-1 and decreases immunosuppression | Safety | Recruiting |
Her2 Inhibitor | NCT03602079 | A166 | None | I/II | Tumour cell apoptosis | Safety, ORR | Recruiting |
CD40 Agonist | NCT03329950 | CDX-1140 | CDX-301,Pembrolizumab | I | Leads to activation of B cells, T cells, DC, macrophages | Safety, dose | Recruiting |
NCT03502330 | APX005M | Cabiralizumab, Nivolumab | I | Safety, tolerability | Recruiting | ||
CD137 agonist | NCT03809624 | INBRX-105 | None | I | T cell co-stimulation, | Safety, dose | Recruiting |
NCT02315066 | PF-05082566 | PF-04518600(OX-40 agonist) | I | Safety, dose | Active not recruiting | ||
STING agonist | NCT03010176 | MK-1454 | Pembrolizumab | I | Production of IFNb, enhanced cross-presentation by APCs | Safety, dose | Recruiting |
RIG-1 agonist | NCT03739138 | MK-46212 | Pembrolizumab | I | Stimulation of IFNs, enhanced anti-tumour response | Safety, dose | Active not recruiting |